Who founded Switch Therapeutics?

Switch Therapeutics was founded by Si-Ping Han, Deepshikha Datta in 2020.

Who are Switch Therapeutics's investors?

Switch Therapeutics's investors include Bold Capital Partners, CRV (Charles River Ventures), Dolby Family Ventures, FREEFLOW, Global Brain, Ono Venture Investment, Inc., Upfront Ventures, Digitalis Ventures and 2 more.

How much funding has Switch Therapeutics raised?

Switch Therapeutics has disclosed $23.3M raised across 1 round.

Where is Switch Therapeutics headquartered?

Switch Therapeutics is headquartered in South San Francisco, US.

Switch Therapeutics

South San Francisco, US · Founded 2020 · Delaware corporation · 28 employees on LinkedIn · 10 known investors

Find your way into Switch Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Switch Therapeutics team. We find them
2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.

AI & Machine Learning Biotech Deep Tech Medical Devices

Founders & leadership

Switch Therapeutics was founded in 2020 by Si-Ping Han and Deepshikha Datta.

Si-Ping HanCo-founder and SAB member

Deepshikha DattaChief Executive Officer and President

Board

Kevin ZhangBoard director

Alicia Irurzun-Lafitte Board directorPartner at UCB Ventures

Dylan Morris Board DirectorManaging Director at Insight Partners

Investors · 10

Bold Capital Partnerslisted by Bold Capital PartnersSanta Monica

How we know: Bold Capital Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

CRV (Charles River Ventures)listed by CRV (Charles River Ventures)Bay Area · $250K – $5M

How we know: CRV (Charles River Ventures)'s portfolio page · Not right? Tell us

Dolby Family Ventureslisted by Dolby Family VenturesSan Francisco

How we know: Dolby Family Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

FREEFLOWlisted by FREEFLOWBerkeley

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Global Brainlisted by Global BrainTokyo · $100K

How we know: Global Brain's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Ono Venture Investment, Inc.listed by Ono Venture Investment, Inc.South San Francisco

How we know: Ono Venture Investment, Inc.'s portfolio page · Not right? Tell us

Upfront Ventureslisted by Upfront VenturesLos Angeles · $1M – $10M

How we know: Upfront Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Digitalis VenturesreportedNew York · $100K – $10M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Insight PartnersreportedNew York · $120M – $350M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

UCB VenturesinferredBrusselsvia Alicia Irurzun-Lafitte · board

How we know: board seat on SEC Form D · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$23.3M disclosed across 1 round · 2022

▶$23.3MraisedNov 2022 · 15 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Kevin ZhangDirector
Alicia Irurzun-LafitteDirector
Dylan MorrisDirector
Si-Ping HanExecutive Officer
Deepshikha DattaExecutive Officer, Director

Offering amount: $36M
Amount sold: $23.3M
First sale: Sep 2022
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 9

Sionna TherapeuticsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.

Silence TherapeuticsSilence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.

SirnaomicsSirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.

RonatherapeuticsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.

Syrna TherapeuticsSyrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.

Sirius TherapeuticsSirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area. It focuses on drug discovery and clinical development of RNA-based medicines.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Serna BioSerna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.

Neurona TherapeuticsNeurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.

Companies working in the same space as Switch Therapeutics.

Frequently asked questions

What does Switch Therapeutics do?: Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
Who founded Switch Therapeutics?: Switch Therapeutics was founded by Si-Ping Han, Deepshikha Datta in 2020.
Who are Switch Therapeutics's investors?: Switch Therapeutics's investors include Bold Capital Partners, CRV (Charles River Ventures), Dolby Family Ventures, FREEFLOW, Global Brain, Ono Venture Investment, Inc., Upfront Ventures, Digitalis Ventures and 2 more.
How much funding has Switch Therapeutics raised?: Switch Therapeutics has disclosed $23.3M raised across 1 round.
Where is Switch Therapeutics headquartered?: Switch Therapeutics is headquartered in South San Francisco, US.